BCI Marketplace
Depression Neuromodulation trials

qEEG Brain Signature of Depression & Neuromodulation-induced Recovery

RecruitingNCT06719427Phase: PHASE1Started 2025-01-06

Summary

This study aims to explore how repetitive transcranial magnetic stimulation (rTMS), a treatment for depression, affects brain function. Depression disrupts the brain's complex network or regions that regulate cognition, emotion, and behavior. rTMS targets these disruptions to restore network function. To measure these effects, researchers will use dry quantitative EEG (qEEG), a new technology that records brain electrical activity quickly (15 minutes compared to 1 hour for traditional EEG) witho

Eligibility

Sex
ALL
Min Age
18 Years
Max Age
80 Years

Inclusion Criteria: * A diagnosis of Depression based on Diagnostic and Statistical Manual (DSM) 5.0 criteria. * Receiving a neuromodulation (rTMS) treatment for depression at the HCN * Physically healthy * Age 18-80, inclusive. * Able to provide informed consent and comply with the study protocol.

Locations

Sunnybrook Health Sciences Centre
North York, Ontario, Canada
Sunnybrook Health Sciences Centre
Toronto, Ontario, Canada

Interested in participating? View the full study details on ClinicalTrials.gov:

View on ClinicalTrials.gov →